Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
neuroendocrine
Biotech
Sanofi pays $110M upfront for late-stage radioligand therapy
Sanofi has made a late entry to the radioligand party, paying 100 million euros for a neuroendocrine tumor drug that is nearing a filing for approval.
Nick Paul Taylor
Sep 12, 2024 4:54am
Crinetics growth disorder drug sees ph. 2 carcinoid syndrome win
Mar 13, 2024 9:16am
Carl June's latest CAR-T work taps llamas for GI cancers
Mar 29, 2022 9:00am
Chi-Med's surufatinib fends off pancreatic tumors in phase 3
Sep 18, 2020 6:05pm
Chi-Med stops pivotal pancreatic cancer trial upon early success
Jan 21, 2020 8:30am
Tiburio launches with $31M and focus on rare endocrine disease
Jan 3, 2019 7:30am